

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

B68

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 19/00 // 14/52, 14/55, 14/705, 14/73</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/43713</b> (43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/US99/03966 (22) International Filing Date: 24 February 1999 (24.02.99) (30) Priority Data: 60/075,887 25 February 1998 (25.02.98) US (71) Applicant: LEXIGEN PHARMACEUTICALS CORPORATION [US/US]; 125 Hartwell Avenue, Lexington, MA 02421 (US). (72) Inventors: GILLIES, Stephen, D.; 159 Sunset Road, Carlisle, MA 01741 (US). LO, Kin-Ming; 6 Carol Lane, Lexington, MA 02173 (US). LAN, Yan; 21 Newton Street, Belmont, MA 02178 (US). WESOLOWSKI, John; 97 Liberty Bell Circle, Weymouth, MA 02189 (US). (74) Agent: WALLER, Patrick, R., H.; Testa, Hurwitz & Thibault, L.L.P., High Street Tower, 125 High Street, Boston, MA 02110 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS  (57) Abstract  Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS

### Cross Reference to Related Application

This incorporates by reference, and claims priority to and the benefit of, U.S. Provisional Patent Application Serial Number 60/075,887 which was filed on February 25, 1998.

### Field of the Invention

5           The present invention relates generally to fusion proteins. More specifically, the present invention relates to methods of enhancing the circulating half-life of antibody-based fusion proteins.

### Background of the Invention

10           The use of antibodies for treatment human disease is well established and has become more sophisticated with the introduction of genetic engineering. Several techniques have been developed to improve the utility of antibodies. These include: (1) the generation of monoclonal antibodies by cell fusion to create "hybridomas", or by molecular cloning of antibody heavy (H) and light (L) chains from antibody-producing cells; (2) the conjugation of other molecules to antibodies to deliver them to preferred sites *in vivo*, e.g., radioisotopes, toxic drugs, protein  
15           toxins, and cytokines; (3) the manipulation of antibody effector functions to enhance or diminish biological activity; (4) the joining of other protein such as toxins and cytokines with antibodies at the genetic level to produce antibody-based fusion proteins; and (5) the joining of one or more sets of antibody combining regions at the genetic level to produce bi-specific antibodies.

20           When proteins are joined together through either chemical or genetic manipulation, it is often difficult to predict what properties that the end product will retain from the parent molecules. With chemical conjugation, the joining process may occur at different sites on the molecules, and generally results in molecules with varying degrees of modification that can affect the function of one or both proteins. The use of genetic fusions, on the other hand, makes the joining process more consistent, and results in the production of consistent end products that  
25           retain the function of both component proteins. See, for example, Gillies *et al.*, PROC. NATL. ACAD. SCI. USA 89: 1428-1432 (1992); and U.S. Patent No. 5,650,150.

- 2 -

However, the utility of recombinantly-produced antibody-based fusion proteins may be limited by their rapid *in vivo* clearance from the circulation. Antibody-cytokine fusion proteins, for example, have been shown to have a significantly lower *in vivo* circulating half-life than the free antibody. When testing a variety of antibody-cytokine fusion proteins, Gillies *et al.* reported  
5 that all of the fusion proteins tested had an  $\alpha$  phase (distribution phase) half-life of less than 1.5 hour. Indeed, most of the antibody-based fusion protein were cleared to 10% of the serum concentration of the free antibody by two hours. See, Gillies *et al.*, BIOCONJ. CHEM. 4: 230-235 (1993). Therefore, there is a need in the art for methods of enhancing the *in vivo* circulating half-life of antibody-based fusion proteins.

10

### Summary of the Invention

A novel approach to enhancing the *in vivo* circulating half-life of antibody-based fusion proteins has now been discovered. Specifically, the present invention provides methods for the production of fusion proteins between an immunoglobulin with a reduced binding affinity for an Fc receptor, and a second non-immunoglobulin protein. Antibody-based fusion proteins with  
15 reduced binding affinity for Fc receptors have a significantly longer *in vivo* circulating half-life than the unlinked second non-immunoglobulin protein.

IgG molecules interact with three classes of Fc receptors (FcR) specific for the IgG class of antibody, namely Fc $\gamma$ RI, Fc $\gamma$ RII and Fc $\gamma$ RIII. In preferred embodiments, the immunoglobulin (Ig) component of the fusion protein has at least a portion of the constant region of an IgG that  
20 has a reduced binding affinity for at least one of Fc $\gamma$ RI, Fc $\gamma$ RII or Fc $\gamma$ RIII.

In one aspect of the invention, the binding affinity of fusion proteins for Fc receptors is reduced by using heavy chain isotypes as fusion partners that have reduced binding affinity for Fc receptors on cells. For example, both human IgG1 and IgG3 have been reported to bind to Fc $\gamma$ RI with high affinity, while IgG4 binds 10-fold less well, and IgG2 does not bind at all. The  
25 important sequences for the binding of IgG to the Fc receptors have been reported to be located in the CH2 domain. Thus, in a preferred embodiment, an antibody-based fusion protein with enhanced *in vivo* circulating half-life is obtained by linking at least the CH2 domain of IgG2 or IgG4 to a second non-immunoglobulin protein.

In another aspect of the invention, the binding affinity of fusion proteins for Fc receptors  
30 is reduced by introducing a genetic modification of one or more amino acid in the constant

- 3 -

region of the IgG1 or IgG3 heavy chains that reduces the binding affinity of these isotypes for Fc receptors. Such modifications include alterations of residues necessary for contacting Fc receptors or altering others that affect the contacts between other heavy chain residues and Fc receptors through induced conformational changes. Thus, in a preferred embodiment, an antibody-based fusion protein with enhanced *in vivo* circulating half-life is obtained by first introducing a mutation, deletion, or insertion in the IgG1 constant region at one or more amino acid selected from Leu<sub>234</sub>, Leu<sub>235</sub>, Gly<sub>236</sub>, Gly<sub>237</sub>, Asn<sub>297</sub>, and Pro<sub>331</sub>, and then linking the resulting immunoglobulin, or portion thereof, to a second non-immunoglobulin protein. In an alternative preferred embodiment, the mutation, deletion, or insertion is introduced in the IgG3 constant region at one or more amino acid selected from Leu<sub>281</sub>, Leu<sub>282</sub>, Gly<sub>283</sub>, Gly<sub>284</sub>, Asn<sub>344</sub>, and Pro<sub>378</sub>, and the resulting immunoglobulin, or portion thereof, is linked to a second non-immunoglobulin protein. The resulting antibody-based fusion proteins have a longer *in vivo* circulating half-life than the unlinked second non-immunoglobulin protein.

In a preferred embodiment, the second non-immunoglobulin component of the fusion protein is a cytokine. The term "cytokine" is used herein to describe proteins, analogs thereof, and fragments thereof which are produced and excreted by a cell, and which elicit a specific response in a cell which has a receptor for that cytokine. Preferably, cytokines include interleukins such as interleukin-2 (IL-2), hematopoietic factors such as granulocyte-macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF) such as TNF $\alpha$ , and lymphokines such as lymphotoxin. Preferably, the antibody-cytokine fusion protein of the present invention displays cytokine biological activity.

In an alternative preferred embodiment, the second non-immunoglobulin component of the fusion protein is a ligand-binding protein with biological activity. Such ligand-binding proteins may, for example, (1) block receptor-ligand interactions at the cell surface; or (2) neutralize the biological activity of a molecule (*e.g.*, a cytokine) in the fluid phase of the blood, thereby preventing it from reaching its cellular target. Preferably, ligand-binding proteins include CD4, CTLA-4, TNF receptors, or interleukin receptors such as the IL-1 and IL-4 receptors. Preferably, the antibody-receptor fusion protein of the present invention displays the biological activity of the ligand-binding protein.

In yet another alternative preferred embodiment, the second non-immunoglobulin component of the fusion protein is a protein toxin. Preferably, the antibody-toxin fusion protein of the present invention displays the toxicity activity of the protein toxin.

In a preferred embodiment, the antibody-based fusion protein comprises a variable region  
5 specific for a target antigen and a constant region linked through a peptide bond to a second non-immunoglobulin protein. The constant region may be the constant region normally associated with the variable region, or a different one, *e.g.*, variable and constant regions from different species. The heavy chain can include a CH1, CH2, and/or CH3 domains. Also embraced within the term "fusion protein" are constructs having a binding domain comprising framework regions  
10 and variable regions (*i.e.*, complementarity determining regions) from different species, such as are disclosed by Winter, *et al.*, GB 2,188, 638. Antibody-based fusion proteins comprising a variable region preferably display antigen-binding specificity. In yet another preferred embodiment, the antibody-based fusion protein further comprises a light chain. The invention thus provides fusion proteins in which the antigen-binding specificity and activity of an antibody  
15 are combined with the potent biological activity of a second non-immunoglobulin protein, such as a cytokine. A fusion protein of the present invention can be used to deliver selectively the second non-immunoglobulin protein to a target cell *in vivo* so that the second non-immunoglobulin protein can exert a localized biological effect.

In an alternative preferred embodiment, the antibody-based fusion protein comprises a  
20 heavy chain constant region linked through a peptide bond to a second non-immunoglobulin protein, but does not comprise a heavy chain variable region. The invention thus further provides fusion proteins which retain the potent biological activity of a second non-immunoglobulin protein, but which lack the antigen-binding specificity and activity of an antibody.

25 In preferred embodiments, the antibody-based fusion proteins of the present invention further comprise sequences necessary for binding to Fc protection receptors (FcRp), such as beta-2 microglobulin-containing neonatal intestinal transport receptor (FcRn).

In preferred embodiments, the fusion protein comprises two chimeric chains comprising at least a portion of a heavy chain and a second, non-Ig protein are linked by a disulfide bond.

The invention also features DNA constructs encoding the above-described fusion proteins, and cell lines, *e.g.*, myelomas, transfected with these constructs.

These and other objects, along with advantages and features of the invention disclosed herein, will be made more apparent from the description, drawings, and claims that follow.

5

### Brief Description of the Drawings

The foregoing and other objects, features, and advantages of the present invention, as well as the invention itself, may be more fully understood from the following description of preferred embodiments, when read together with the accompanying drawings, in which:

FIG. 1 is a homology alignment of the amino acid sequences of the constant region of C $\gamma$ 1 and C $\gamma$ 3, aligned to maximize amino acid identity, and wherein non-conserved amino acids are identified by boxes;

FIG. 2 is a homology alignment of the amino acid sequences of constant region of C $\gamma$ 1, C $\gamma$ 2, and C $\gamma$  4, aligned to maximize amino acid identity, and wherein non-conserved amino acids are identified by boxes;

FIG. 3 is a diagrammatic representation of a map of the genetic construct encoding an antibody-based fusion protein showing the relevant restriction sites;

FIG. 4 is a bar graph depicting the binding of antibody hu-KS-1/4 and antibody-based fusion proteins, hu-KS $\gamma$ 1-IL2 and hu-KS $\gamma$ 4-IL2, to Fc receptors on mouse J774 cells in the presence (solid bars) or absence (stippled bars) of an excess of mouse IgG;

FIG. 5 is a line graph depicting the *in vivo* plasma concentration of total antibody (free antibody and fusion protein) of hu-KS $\gamma$ 1-IL2 (closed diamond) and hu-KS $\gamma$ 4-IL2 (closed triangle) and of intact fusion protein of hu-KS $\gamma$ 1-IL2 (open diamond) and hu-KS $\gamma$ 4-IL2 (open triangle) as a function of time;

FIG. 6 is a diagrammatic representation of protocol for constructing an antibody-based fusion protein with a mutation that reduces the binding affinity to Fc receptors;

FIG. 7 is a line graph depicting the *in vivo* plasma concentration of intact fusion protein of hu-KS $\gamma$ 1-IL2 (○); mutated hu-KS $\gamma$ 1-IL2 (⊗) and hu-KS $\gamma$ 4-IL2 (Δ) as a function of time.

- 6 -

### Detailed Description of the Invention

It has now been discovered that fusing a second protein, such as a cytokine, to an immunoglobulin may alter the antibody structure, resulting in an increase in binding affinity for one or more of the cell-bound Fc receptors and leading to a rapid clearance of the antibody-based fusion protein from the circulation. The present invention describes antibody-based fusion proteins with enhanced *in vivo* circulating half-lives and involves producing, through recombinant DNA technology, antibody-based fusion proteins with reduced binding affinity for one or more Fc receptor.

First, an antibody-based fusion protein with an enhanced *in vivo* circulating half-life can be obtained by constructing a fusion protein with isotypes having reduced binding affinity for a Fc receptor, and avoiding the use of sequences from antibody isotypes that bind to Fc receptors. For example, of the four known IgG isotypes, IgG1 (C $\gamma$ 1) and IgG3 (C $\gamma$ 3) are known to bind FcR $\gamma$ I with high affinity, whereas IgG4 (C $\gamma$ 4) has a 10-fold lower binding affinity, and IgG2 (C $\gamma$ 2) does not bind to FcR $\gamma$ I. Thus, an antibody-based fusion protein with reduced binding affinity for a Fc receptor could be obtained by constructing a fusion protein with a C $\gamma$ 2 constant region (Fc region) or a C $\gamma$ 4 Fc region, and avoiding constructs with a C $\gamma$ 1 Fc region or a C $\gamma$ 3 Fc region.

Second, an antibody-based fusion protein with an enhanced *in vivo* circulating half-life can be obtained by modifying sequences necessary for binding to Fc receptors in isotypes that have binding affinity for an Fc receptor, in order to reduce or eliminate binding. As mentioned above, IgG molecules interact with three classes of Fc receptors (FcR), namely Fc $\gamma$ R I, Fc $\gamma$ R II, and Fc $\gamma$ R III. C $\gamma$ 1 and C $\gamma$ 3 bind FcR $\gamma$ I with high affinity, whereas C $\gamma$ 4 and C $\gamma$ 2 have reduced or no binding affinity for FcR $\gamma$ I. A comparison of the C $\gamma$ 1 and C $\gamma$ 3 indicates that, with the exception of an extended hinge segment in C $\gamma$ 3, the amino acid sequence homology between these two isotypes is very high. This is true even in those regions that have been shown to interact with the C1q fragment of complement and the various Fc $\gamma$ R classes. FIG. 1 provides a alignment of the amino acid sequences of C $\gamma$ 1 and C $\gamma$ 3. The other two isotypes of human IgG (C $\gamma$ 2 and C $\gamma$ 4) have sequence differences which have been associated with FcR binding. FIG. 2 provides a alignment of the amino acid sequences of C $\gamma$ 1, C $\gamma$ 2, and C $\gamma$ 4. The important



- 7 -

sequences for FcγR binding are Leu-Leu-Gly-Gly (residues 234 through 237 in Cγ1), located in the CH2 domain adjacent to the hinge. Canfield and Morrison, J. EXP. MED. 173: 1483-1491 (1991). These sequence motifs are conserved in Cγ1 and Cγ3, in agreement with their similar biological properties, and possibly related to the similarity of pharmacokinetic behavior when used to construct IL-2 fusion proteins. Many mutational analyses have been done to demonstrate the effect of specific mutations on FcR binding, including those in residues 234-237 as well as the hinge-proximal bend residue Pro<sub>331</sub>, that is substituted by Ser in IgG4. Another important structural component necessary for effective FcR binding is the presence of an N-linked carbohydrate chain covalently bound to Asn<sub>297</sub>. Enzymatic removal of this structure or mutation of the Asn residue effectively abolish, or at least dramatically reduce, binding to all classes of FcγR.

Brumbell *et al.* postulated the existence of a protection receptor (FcRp) that would slow the rate of catabolism of circulating antibodies by binding to the Fc portion of antibodies and, following their pinocytosis into cells, would redirect them back into the circulation. Brumbell *et al.*, NATURE 203: 1352-1355 (1964). The beta-2 microglobulin-containing neonatal intestinal transport receptor (FcRn) has recently been identified as a FcRp. See, Junghans *et al.*, PROC. NATL. ACAD. SCI. USA 93: 5512-5516 (1996). The sequences necessary for binding to this receptor are conserved in all four classes of human IgG and are located at the interface between the CH2 and CH3 domains. See, Medesan *et al.*, J. IMMUNOL. 158: 2211-2217 (1997). These sequences have been reported to be important for the *in vivo* circulating half-life of antibodies. See, International PCT publication WO 97/34631. Thus, preferred antibody-based fusion proteins of the present invention will have the sequences necessary for binding to FcRp.

Methods for synthesizing useful embodiments of the invention are described, as well as assays useful for testing their pharmacokinetic activities, both *in vitro* and in pre-clinical *in vivo* animal models. The preferred gene construct encoding a chimeric chain includes, in 5' to 3' orientation, a DNA segment which encodes at least a portion of an immunoglobulin and DNA which encodes a second, non-immunoglobulin protein. An alternative preferred gene construct includes, in 5' to 3' orientation, a DNA segment which encodes a second, non-immunoglobulin protein and DNA which encodes at least a portion of an immunoglobulin. The fused gene is assembled in or inserted into an expression vector for transfection of the appropriate recipient cells where it is expressed.

- 8 -

The invention is illustrated further by the following non-limiting examples:

**Example 1    Improving the *in vivo* circulating half-life of an antibody-IL2 fusion protein by class switching from C $\gamma$ 1 to C $\gamma$ 4 IgG constant regions.**

According to the present invention, antibody-based fusion proteins with enhanced *in vivo* circulating half-lives can be obtained by constructing antibody-based fusion proteins using sequences from antibody isotypes that have reduced or no binding affinity for Fc receptors.

In order to assess whether the *in vivo* circulating half-life of the antibody-based fusion protein can be enhanced by using sequences from antibody isotypes with reduced or no binding affinity for Fc receptors, an antibody-IL2 fusion protein with a human C $\gamma$ 1 constant region (Fc region) was compared to an antibody-IL2 fusion protein with a human C $\gamma$ 4 Fc region.

**1.1    Construction of antibody-IL2 fusion proteins with a C $\gamma$ 4 IgG constant region.**

The construction of antibody-IL2 fusion proteins with a C $\gamma$ 1 constant region has been described in the prior art. See, for example, Gillies *et al.*, PROC. NATL. ACAD. SCI. USA 89: 1428-1432 (1992); and U.S. Patent No 5,650,150, the disclosure of which is incorporated herein by reference.

To construct antibody-IL2 fusion proteins with a C $\gamma$ 4 constant region, a plasmid vector, capable of expressing a humanized antibody-IL2 fusion protein with variable (V) regions specific for a human pancarcinoma antigen (KSA) and the human C $\gamma$ 1 heavy chain fused to human IL-2, was modified by removing the C $\gamma$ 1 gene fragment and replacing it with the corresponding sequence from the human C $\gamma$ 4 gene. A map of some of the relevant restriction sites and the site of insertion of the C $\gamma$ 4 gene fragment is provided in FIG. 3. These plasmid constructs contain the cytomegalovirus (CMV) early promoter for transcription of the mRNA encoding the light (L) and heavy (H) chain variable (V) regions derived from the mouse antibody KS-1/4. The mouse V regions were humanized by standard methods and their encoding DNA sequences were chemically synthesized. A functional splice donor site was added at the end of each V region so that it could be used in vectors containing H and L chain constant region genes. The human C $\kappa$  light chain gene was inserted downstream of the cloning site for the VL gene and was followed by its endogenous 3' untranslated region and poly adenylation site. This transcription unit was followed by a second independent transcription unit for the heavy chain-IL2 fusion protein. It is

- 9 -

also driven by a CMV promoter. The VH encoding sequence was inserted upstream of the DNA encoding the Cy heavy chain gene of choice, fused to human IL-2 encoding sequences. Such Cy genes contain splice acceptor sites for the first heavy chain exon (CH1), just downstream from a unique Hind III common to all human Cy genes. A 3' untranslated and polyadenylation site from SV40 virus was inserted at the end of the IL-2 encoding sequence. The remainder of the vector contained bacterial plasmid DNA necessary for propagation in *E. coli* and a selectable marker gene (dihydrofolate reductase - dhfr) for selection of transfectants of mammalian cells.

The swapping of the Cy1 and Cy4 fragments was accomplished by digesting the original Cy1-containing plasmid DNA with Hind III and Xho I and purifying the large 7.8 kb fragment by agarose gel electrophoresis. A second plasmid DNA containing the Cy4 gene was digested with Hind III and Nsi I and the 1.75 kb fragment was purified. A third plasmid containing the human IL-2 cDNA and SV40 poly A site, fused to the carboxyl terminus of the human Cy1 gene, was digested with Xho I and Nsi I and the small 470 bp fragment was purified. All three fragments were ligated together in roughly equal molar amounts and the ligation product was used to transform competent *E. coli*. The ligation product was used to transform competent *E. coli* and colonies were selected by growth on plates containing ampicillin. Correctly assembled recombinant plasmids were identified by restriction analyses of plasmid DNA preparations from isolated transformants and digestion with Fsp I was used to discriminate between the Cy1 (no Fsp I) and Cy4 (one site) gene inserts. The final vector, containing the Cy4-IL2 heavy chain replacement, was introduced into mouse myeloma cells and transfectants were selected by growth in medium containing methotrexate (0.1  $\mu$ M). Cell clones expressing high levels of the antibody-IL2 fusion protein were expanded and the fusion protein was purified from culture supernatants using protein A Sepharose chromatography. The purity and integrity of the Cy4 fusion protein was determined by SDS-polyacrylamide gel electrophoresis. IL-2 activity was measured in a T-cell proliferation assay and found to be identical to that of the Cy1 construct.

#### ***1.2 Binding to Fc receptors by antibody and antibody-IL2 fusion proteins with Cy1 and Cy4 IgG constant region.***

Various mouse and human cell lines express one or more Fc receptor. For example, the mouse J774 macrophage-like cell line expresses FcR $\gamma$ 1 that is capable of binding mouse or human IgG of the appropriate subclasses. Likewise, the human K562 erythroleukemic cell line

- 10 -

expresses FcRyII but not FcRyI. In order to assess the potential contribution of Fc receptor binding to clearance of antibody-based fusion proteins from the circulation, the binding affinities of an antibody, a Cy1-IL2 fusion protein, and a Cy4-IL2 fusion protein for FcRyI were compared in the mouse J774 cell line.

5           The two antibody-IL-2 fusion proteins described in Example 1, hu-KSy1-IL2 and hu-KSy4-IL2, were diluted to 2 µg/ml in PBS containing 0.1% bovine serum albumin (BSA), together with  $2 \times 10^5$  J774 cells in a final volume of 0.2 ml. After incubation on ice for 20 min, a FITC-conjugated anti-human IgG Fc antibody (Fab<sub>2</sub>) was added and incubation was continued for an additional 30 min. Unbound antibodies were removed by two washes with PBS-BSA, and  
10          the cells were analyzed in a fluorescence-activated cell sorter (FACS). Control reactions contained the same cells mixed with just the FITC-labeled secondary antibody or with the humanized KSy1 antibody (without IL-2).

As expected, the binding of the Cy4-IL2 fusion protein to J774 cells was significantly lower than the binding of the Cy1-IL2 fusion protein. See FIG. 4. Unexpectedly, however, both  
15          the Cy1-IL2 and Cy4-IL2 fusion proteins had significantly higher binding to J774 cells than the KSy1 antibody (without IL-2). This suggests that fusing a second protein, such as a cytokine, to an immunoglobulin may alter the antibody structure, resulting in an increase in binding affinity for one or more of the cell-bound Fc receptors, thereby leading to a rapid clearance from the circulation.

20           In order to determine whether the greater binding observed with IL-2 fusion proteins was due to the presence of IL-2 receptors or FcRyI receptors on the cells, excess mouse IgG (mIgG) was used to compete the binding at the Fc receptors. As illustrated in FIG. 4, background levels of binding were observed with the antibody and both antibody-IL2 fusion proteins in the presence of a 50-fold molar excess of mIgG. This suggests that the increased signal binding of  
25          antibody-IL2 fusion proteins was due to increased binding to the Fc receptor.

Cell lines expressing Fc receptors are useful for testing the binding affinities of candidate fusion proteins to Fc receptors in order to identify antibody-based fusion proteins with enhanced *in vivo* half lives. Candidate antibody-based fusion proteins can be tested by the above-described methods. Candidate antibody-based fusion proteins with substantially reduced binding affinity

for an Fc receptor will be identified as antibody-based fusion proteins with enhanced *in vivo* half lives.

**1.3 Measuring the circulating half-life of antibody-IL2 fusion proteins with C $\gamma$ 1 and C $\gamma$ 4 IgG constant region.**

5 In order to assess whether using the Fc region of an IgG isotype having reduced affinity for Fc receptors will enhance the *in vivo* circulating half-life, fusion proteins containing the C $\gamma$ 1 isotype heavy chain (*i.e.*, hu-KSy1-IL2) were compared to fusion proteins containing the C $\gamma$ 4 isotype heavy chain (*i.e.*, hu-KSy4-IL2).

Purified humanized KS-1/4-IL2 fusion proteins containing either the C $\gamma$ 1 or C $\gamma$ 4 isotype  
10 heavy chain were buffer-exchanged by diafiltration into phosphate buffered saline (PBS) and diluted further to a concentration of ~100  $\mu$ g/ml. Approximately 20  $\mu$ g of the antibody-based fusion protein (0.2 ml) was injected into 6-8 week old Balb/c mice in the tail vein using a slow push. Four mice were injected per group. At various time points, small blood samples were taken by retro-orbital bleeding from anaesthetized animals and collected in tubes containing  
15 citrate buffer to prevent clotting. Cells were removed by centrifugation in an Eppendorf high-speed tabletop centrifuge for 5 min. The plasma was removed with a micropipettor and frozen at -70°C. The concentration of human antibody determinants in the mouse blood was measured by ELISA. A capture antibody specific for human H and L antibody chains was used for capture of the fusion proteins from the diluted plasma samples. After a two hour incubation  
20 in antibody-coated 96-well plates, the unbound material was removed by three washes with ELISA buffer (0.01% Tween 80 in PBS). A second incubation step used either an anti-human Fc antibody (for detection of both antibody and intact fusion protein), or an anti-human IL-2 antibody (for detection of only the intact fusion protein). Both antibodies were conjugated to horse radish peroxidase (HRP). After a one hour incubation, the unbound detecting antibody  
25 was removed by washing with ELISA buffer and the amount of bound HPR was determined by incubation with substrate and measuring in a spectrophotometer.

As depicted in FIG. 5, the  $\alpha$  phase half-life of the hu-KSy4-IL2 fusion protein was significantly longer than the  $\alpha$  phase half-life of the hu-KSy1-IL2 fusion protein. The increased half-life is best exemplified by the significantly higher concentrations of the hu-KSy4-IL2 fusion

- 12 -

protein (3.3 µg/ml) compared to the hu-KSy1-IL2 fusion protein (60 ng/ml) found in mice after 24 hours.

The hu-KSy1-IL2 protein had a rapid distribution ( $\alpha$ ) phase followed by a slower catabolic ( $\beta$ ) phase, as reported earlier for the chimeric 14.18-IL2 fusion protein. See, Gillies *et al.*, BIOCONJ. CHEM. 4: 230-235 (1993). In the Gillies *et al.* study, only antibody determinants were measured, so it was not clear if the clearance represented the clearance of the intact fusion protein or the clearance of the antibody component of the fusion protein. In the present Example, samples were assayed using both (1) an antibody-specific ELISA, and (2) a fusion protein-specific ELISA (*i.e.*, an ELISA that requires that both the antibody and IL-2 components be physically linked). As illustrated in FIG. 5, in animals injected with the hu-KSy1-IL2 fusion protein, the amount of circulating fusion protein was lower than the total amount of circulating antibody, especially at the 24 hr time point. This suggests that the fusion protein is being proteolytically cleaved *in vivo* and that the released antibody continues to circulate. Surprisingly, in animals injected with the hu-KSy4-IL2 fusion protein, there was no significant differences between the amount of circulating fusion protein and the total amount of circulating antibody. This suggests the hu-KSy4-IL2 fusion protein was not being proteolytically cleaved in these animals during the 24 hour period measured.

As discussed above, Cy1 and Cy3 have binding affinity for Fc receptors, whereas while Cy4 has reduced binding affinity and Cy2 has no binding affinity for Fc receptors. The present Example described methods for producing antibody-based fusion proteins using the Cy4 Fc region, an IgG isotype having reduced affinity for Fc receptors, and established that such antibody-based fusion proteins have enhanced *in vivo* circulating half-life. Accordingly, a skilled artisan can use these methods to produce antibody-based fusion proteins with the Cy2 Fc region, instead of the Cy4 Fc region, in order to enhance the circulating half-life of fusion proteins. A Hu-KS-IL2 fusion protein utilizing the human Cy2 region can be constructed using the same restriction fragment replacement and the above-described methods for Cy4-IL2 fusion protein. and tested using the methods described herein to demonstrate increased circulating half-life. Antibody-based fusion proteins with the Cy2 Fc region, or any other Fc region having reduced binding affinity or lacking binding affinity for a Fc receptor will have enhanced *in vivo*

- 13 -

circulating half-life compared to antibody-based fusion proteins having binding affinity for a Fc receptor.

**Example 2 Mutating the human C $\gamma$ 1 or C $\gamma$ 3 gene in antibody-based fusion protein constructs to improve their *in vivo* circulating half-life.**

5 IgG molecules interact with several molecules in the circulation, including members of the complement system of proteins (*e.g.*, C1q fragment), as well as the three classes of FcR. The important residues for C1q binding are residues Glu<sub>318</sub>, Lys<sub>320</sub>, and Lys<sub>322</sub> which are located in the CH2 domains of human heavy chains. Tao *et al.*, J. EXP. MED. 178: 661-667 (1993). In order to discriminate between FcR and C1q binding as mechanisms for rapid clearance, we substituted  
10 the more drastically altered C $\gamma$ 2 hinge-proximal segment into the C $\gamma$ 1 heavy chain. This mutation is expected to affect FcR binding but not complement fixation.

The mutation was achieved by cloning and adapting the small region between the hinge and the beginning of the CH2 exon of the germ line C $\gamma$ 1 gene using overlapping polymerase chain reactions (PCR). The PCR primers were designed to substitute the new sequence at the  
15 junction of two adjacent PCR fragments spanning a Pst I to Drd I fragment (see FIG. 6). In the first step, two separate PCR reactions with primers 1 and 2 (SEQ ID NOS: 5 and 6, respectively), or primers 3 and 4 (SEQ ID NOS: 7 and 8, respectively), were prepared using the C $\gamma$ 1 gene as the template. The cycle conditions for the primary PCR were 35 cycles of: 94°C for 45 sec, annealing at 48°C for 45 seconds, and primer extension at 72°C for 45 sec. The products of each  
20 PCR reaction were used as template for the second, joining reaction step. One tenth of each primary reaction was mixed together and combined with primers 1 and 4 to amplify only the combined product of the two initial PCR products. The conditions for the secondary PCR were: 94°C for 1 min, annealing at 51°C for 1 min, and primer extension at 72°C for 1 min. Joining occurs as a result of the overlapping between the two individual fragments which pairs with the  
25 end of the other, following denaturation and annealing. The fragments that form hybrids get extended by the Taq polymerase, and the complete, mutated product was selectively amplified by the priming of the outer primers, as shown in FIG. 6. The final PCR product was cloned in a plasmid vector and its sequence verified by DNA sequence analysis.

The assembly of the mutated gene was done in multiple steps. In the first step, a cloning  
30 vector containing the human C $\gamma$ 1 gene was digested with Pst I and Xho I to remove the

- 14 -

non-mutated hinge-CH2-CH3 coding sequences. A *Drd* I to *Xho* I fragment encoding part of CH2, all of CH3 and the fused human IL-2 coding sequences was prepared from the *Cy1*-IL2 vector, described above. A third fragment was prepared from the subcloned PCR product by digestion with *Pst* I and *Drd* I. All three fragments were purified by agarose gel electrophoresis and ligated together in a single reaction mixture. The ligation product was used to transform competent *E. coli* and colonies were selected by growth on plates containing ampicillin. Correctly assembled recombinant plasmids were identified by restriction analyses of plasmid DNA preparations from isolated transformants and mutated genes were confirmed by DNA sequence analysis. The *Hind* III to *Xho* I fragment from the mutated *Cy1*-IL2 gene was used to reassemble the complete hu-KS antibody-IL2 fusion protein expression vector.

In order to assess the enhancement of the *in vivo* circulating half-life induced by a mutation of an important amino acid for FcR binding, and to discriminate between FcR and C1q binding as mechanisms for rapid clearance, the *in vivo* plasma concentration of the mutated hu-KSy1-IL2 was compared to the plasma concentration of hu-KSy1-IL2 at various specified times. As illustrated in FIG. 7, the *in vivo* clearance rates of the mutated hu-KSy1-IL2 and hu-KSy4-IL2 were significantly lower than the clearance rate of hu-KSy1-IL2. These results suggests that an antibody-based fusion protein with enhanced *in vivo* circulating half-life can be obtained by modifying sequences necessary for binding to Fc receptors in isotypes that have binding affinity for an Fc receptor. Further, the results suggests that the mechanisms for rapid clearance involve FcR binding rather than C1q binding.

The skilled artisan will understand, from the teachings of the present invention, that several other mutations to the *Cy1* or *Cy3* genes can be introduced in order to reduce binding to FcR and enhance the *in vivo* circulating half-life of an antibody-based fusion protein. Moreover, mutations can also be introduced into the *Cy4* gene in order to further reduce the binding of *Cy4* fusion proteins to FcR. For example, additional possible mutations include mutations in the hinge proximal amino acid residues, mutating Pro<sub>331</sub>, or by mutating the single N-linked glycosylation site in all IgG Fc regions. The latter is located at Asn<sub>297</sub> as part of the canonical sequence: Asn-X-Thr/Ser, where the second position can be any amino acid (with the possible exception of Pro), and the third position is either Thr or Ser. A conservative mutation to the amino acid Gln, for example, would have little effect on the protein but would prevent the



- 15 -

attachment of any carbohydrate side chain. A strategy for mutating this residue might follow the general procedure, just described, for the hinge proximal region. Methods for generating point mutations in cloned DNA sequences are well established in the art and commercial kits are available from several vendors for this purpose.

5   **Example 3   Increasing the circulating half-life of receptor-antibody-based fusion proteins.**

Several references have reported that the Fc portion of human IgG can serve as a useful carrier for many ligand-binding proteins, or receptors, with biological activity. Some of these ligand-binding proteins have been fused to the N-terminal of the Fc portion of an Ig, such as  
10   CD4, CTLA-4, and TNF receptors. See, for example, Capon *et al.*, NATURE 337: 525-531 (1989); Linsley *et al.*, J. EXP. MED. 174: 561-569 (1991); Wooley *et al.*, J. IMMUNOL. 151: 6602-6607 (1993). Increasing the circulating half-life of receptor-antibody-based fusion proteins may permit the ligand-binding protein partner (*i.e.*, the second non-Ig protein) to more effectively  
15   (1) block receptor-ligand interactions at the cell surface; or (2) neutralize the biological activity of a molecule (*e.g.*, a cytokine) in the fluid phase of the blood, thereby preventing it from reaching its cellular target. In order to assess whether reducing the ability of receptor-antibody-based fusion proteins to bind to IgG receptors will enhance their *in vivo* circulating half-life, receptor-antibody-based fusion proteins with human C $\gamma$ 1 Fc regions are compared to antibody-based fusion proteins with human C $\gamma$ 4 Fc regions.

20       To construct CD4-antibody-based fusion proteins, the ectodomain of the human CD4 cell surface receptor is cloned using PCR from human peripheral blood monocytic cells (PBMC). The cloned CD4 receptor includes compatible restriction sites and splice donor sites described in Example 1. The expression vector contains a unique Xba I cloning site downstream of the CMV early promoter, and the human C $\gamma$ 1 or C $\gamma$ 4 gene downstream of their endogenous Hind III site.  
25   The remainder of the plasmid contains bacterial genetic information for propagation in *E. coli*, as well as a dhfr selectable marker gene. Ligated DNAs are used to transform competent bacteria and recombinant plasmids are identified from restriction analyses from individual bacterial colonies. Two plasmid DNA constructs are obtained: CD4-C $\gamma$ 1 and CD4-C $\gamma$ 4.

30       The expression plasmids are used to transfect mouse myeloma cells by electroporation and transfectants are selected by growth in culture medium containing methotrexate (0.1  $\mu$ M).

- 16 -

Transfectants expressing the fusion proteins are identified by ELISA analyses and are expanded in culture in order to generate fusion protein for purification by binding to and elution from protein A Sepharose. Purified proteins in chromatography elution buffer are diafiltered into PBS and diluted to a final concentration of 100 µg/ml. Balb/c mice are injected with 0.2 ml (20 µg) of either the CD4-Cy1 or CD4-Cy4 fusion protein and the pharmacokinetics are tested as described in Example 1.3. The CD4-Cy4 fusion protein has a significantly greater half-life than the CD4-Cy1 fusion protein.

### Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

- 17 -

What is claimed is:

- 1 1. An antibody-based fusion protein with an enhanced circulating half-life, comprising at  
2 least a portion of an immunoglobulin (Ig) heavy chain having substantially reduced  
3 binding affinity for an Fc receptor, said portion of heavy chain being linked to a second  
4 non-Ig protein, said antibody-based fusion protein having a longer circulating half-life *in*  
5 *vivo* than an unlinked second non-Ig protein.
- 1 2. The antibody-based fusion protein of claim 1, wherein said portion of heavy chain  
2 comprises at least the CH2 domain of an IgG2 or IgG4 constant region.
- 1 3. The antibody-based fusion protein of claim 1, wherein said portion of heavy chain  
2 comprises at least a portion of an IgG1 constant region having a mutation or a deletion at  
3 one or more amino acid selected from the group consisting of Leu<sub>234</sub>, Leu<sub>235</sub>, Gly<sub>236</sub>,  
4 Gly<sub>237</sub>, Asn<sub>297</sub>, and Pro<sub>331</sub>.
- 1 4. The antibody-based fusion protein of claim 1, wherein said portion of heavy chain  
2 comprises at least a portion of an IgG3 constant region having a mutation or a deletion at  
3 one or more amino acid selected from the group consisting of Leu<sub>281</sub>, Leu<sub>282</sub>, Gly<sub>283</sub>,  
4 Gly<sub>284</sub>, Asn<sub>344</sub>, and Pro<sub>378</sub>.
- 1 5. The antibody-based fusion protein of claim 1, wherein said portion of heavy chain further  
2 has binding affinity for an immunoglobulin protection receptor.
- 1 6. The antibody-based fusion protein of claim 1, wherein said portion of heavy chain has  
2 substantially reduced binding affinity for a Fc receptor selected from the group consisting  
3 of FcγRI, FcγRII and FcγRIII.
- 1 7. The antibody-based fusion protein of claim 1, wherein said second non-Ig protein is  
2 selected from the group consisting of a cytokine, a ligand-binding protein, and a protein  
3 toxin.
- 1 8. The antibody-based fusion protein of claim 1, wherein said cytokine is selected from the  
2 group consisting of a tumor necrosis factor, an interleukin, and a lymphokine.
- 1 9. The antibody-based fusion protein of claim 8, wherein said tumor necrosis factor is tumor  
2 necrosis factor alpha.
- 1 10. The antibody-based fusion protein of claim 8, wherein said interleukin is interleukin-2.

- 18 -

- 1 11. The antibody-based fusion protein of claim 8, wherein said lymphokine is a lymphotoxin  
2 or a colony stimulating factor.
- 1 12. The antibody-based fusion protein of claim 11, wherein said colony stimulating factor is  
2 a granulocyte-macrophage colony stimulating factor.
- 1 13. The antibody-based fusion protein of claim 1, wherein said ligand-binding protein is  
2 selected from the group consisting of CD4, CTLA-4, TNF receptor, and an interleukin  
3 receptor.
- 1 14. A method of increasing the circulating half-life of an antibody-based fusion protein,  
2 comprising the step of linking at least a portion of an Ig heavy chain to a second non-Ig  
3 protein, said portion of heavy chain having substantially reduced binding affinity for an  
4 Fc receptor, thereby forming an antibody-based fusion protein having a longer circulating  
5 half-life *in vivo* than an unlinked second non-Ig protein.
- 1 15. The method of claim 14, wherein said portion of heavy chain comprises at least the CH2  
2 domain of an IgG2 or IgG4 constant region.
- 1 16. A method of increasing the circulating half-life of an antibody-based fusion protein,  
2 comprising the steps of:
- 3 (a) introducing a mutation or a deletion at one or more amino acid of an IgG1  
4 constant region, said amino acid selected from the group consisting of Leu<sub>234</sub>,  
5 Leu<sub>235</sub>, Gly<sub>236</sub>, Gly<sub>237</sub>, Asn<sub>297</sub>, and Pro<sub>331</sub>, thereby producing an Ig heavy chain  
6 having substantially reduced binding affinity for an Fc receptor; and
- 7 (b) linking at least a portion of the heavy chain of step (a) to a second non-Ig protein,  
8 thereby forming an antibody-based fusion protein having a longer circulating half-life *in*  
9 *vivo* than an unlinked second non-Ig protein.
- 1 17. A method of increasing the circulating half-life of an antibody-based fusion protein,  
2 comprising the steps of:
- 3 (a) introducing a mutation or a deletion at one or more amino acid of an IgG3  
4 constant region, said amino acid selected from the group consisting of Leu<sub>281</sub>,  
5 Leu<sub>282</sub>, Gly<sub>283</sub>, Gly<sub>284</sub>, Asn<sub>344</sub>, and Pro<sub>378</sub>, thereby producing an Ig heavy chain  
6 having substantially reduced binding affinity for an Fc receptor; and

- 19 -

- 7 (b) linking at least a portion of the Ig heavy chain of step (a) to a second non-Ig  
8 protein,  
9 thereby forming an antibody-based fusion protein having a longer circulating half-life *in*  
10 *vivo* than an unlinked second non-Ig protein.
- 1 18. The method of claim 14, 16 or 17, wherein said portion of heavy chain further has  
2 binding affinity for an immunoglobulin protection receptor.
- 1 19. The method of claim 14, 16 or 17, wherein said portion of heavy chain has substantially  
2 reduced binding affinity for a Fc receptor selected from the group consisting of FcγRI,  
3 FcγRII and FcγRIII.
- 1 20. The method of claim 14, 16 or 17, wherein said second non-Ig protein is selected from  
2 the group consisting of a cytokine, a ligand-binding protein, and a protein toxin.
- 1 21. The method of claim 14, 16 or 17, wherein said cytokine is selected from the group  
2 consisting of a tumor necrosis factor, an interleukin, and a lymphokine.
- 1 22. The method of claim 21, wherein said tumor necrosis factor is tumor necrosis factor  
2 alpha.
- 1 23. The method of claim 21, wherein said interleukin is interleukin-2.
- 1 24. The method of claim 21, wherein said lymphokine is a lymphotoxin or a colony  
2 stimulating factor.
- 1 25. The antibody-based fusion protein of claim 24, wherein said colony stimulating factor is  
2 a granulocyte-macrophage colony stimulating factor.
- 1 26. The method of claim 14, 16 or 17, wherein said ligand-binding protein is selected from  
2 the group consisting of CD4, CTLA-4, TNF receptor, and an interleukin receptor.

FIG. 1A

FIG. 1A	FIG. 1B
---------	---------

Fig. 1

2/9

274 K F N W Y V D G V E V H N A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W GC1/118\_HUMAN  
 321 Q F K W Y V D G V E V H N A K T K P R E E Q Y N S T F R V V S V L T V L H Q D W GC3\_HUMAN/118  
 314 L N G K E Y K C K V S N K A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P GC1/118\_HUMAN  
 361 L N G K E Y K C K V S N K A L P A P I E K T I S K T K G Q P R E P Q V Y T L P P GC3\_HUMAN/118  
 354 S R D E L T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T GC1/118\_HUMAN  
 401 S R E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S S G Q P E N N Y N T GC3\_HUMAN/118  
 394 T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L H GC1/118\_HUMAN  
 441 T P P M L D S D G S F F L Y S K L T V D K S R W Q Q G N I F S C S V M H E A L H GC3\_HUMAN/118  
 434 N H Y T Q K S L S L S P G K GC1/118\_HUMAN  
 481 N R F T Q K S L S L S P G K GC3\_HUMAN/118

FIG. 1B




FIG. 2

	10	20	30	40	
1	X	X	X	X	GC1/118_HUMAN
1	X	X	X	X	GC2/118_HUMAN
1	X	X	X	X	GC4/118_HUMAN
41	X	X	X	X	GC1/118_HUMAN
41	X	X	X	X	GC2/118_HUMAN
41	X	X	X	X	GC4/118_HUMAN
81	X	X	X	X	GC1/118_HUMAN
81	X	X	X	X	GC2/118_HUMAN
81	X	X	X	X	GC4/118_HUMAN
121	K	G	P	S	GC1/118_HUMAN
121	K	G	P	S	GC2/118_HUMAN
121	K	G	P	S	GC4/118_HUMAN
161	G	A	L	T	GC1/118_HUMAN
161	G	A	L	T	GC2/118_HUMAN
161	G	A	L	T	GC4/118_HUMAN
201	N	V	N	H	GC1/118_HUMAN
201	N	V	D	H	GC2/118_HUMAN
201	N	V	D	H	GC4/118_HUMAN



	250	260	270	280	
241	F L F P P K P K D T L M I S R T P E V T C V V V D V S H E D P E V K F N W Y V D				GC1/118_HUMAN
237	F L F P P K P K D T L M I S R T P E V T C V V V D V S H E D P E V Q F N W Y V D				GC2/118_HUMAN
238	F L F P P K P K D T L M I S R T P E V T C V V V D V S Q E D P E V Q F N W Y V D				GC4/118_HUMAN
	290	300	310	320	
281	G V E V H N A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K				GC1/118_HUMAN
277	G V E V H N A K T K P R E E Q F N S T F R V V S V L T V V H Q D W L N G K E Y K				GC2/118_HUMAN
278	G V E V H N A K T K P R E E Q F N S T Y R V V S V L T V L H Q D W L N G K E Y K				GC4/118_HUMAN
	330	340	350	360	
321	C K V S N K A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P S R D E L T K				GC1/118_HUMAN
317	C K V S N K G L P A P I E K T I S K T K G Q P R E P Q V Y T L P P S R E E M T K				GC2/118_HUMAN
318	C K V S N K G L P S S I E K T I S K T K G Q P R E P Q V Y T L P P S Q E E M T K				GC4/118_HUMAN
	370	380	390	400	
361	N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S				GC1/118_HUMAN
357	N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P M L D S				GC2/118_HUMAN
358	N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S				GC4/118_HUMAN
	370	380	390	400	
401	D G S F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L H N H Y T Q K S				GC1/118_HUMAN
397	D G S F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L H N H Y T Q K S				GC2/118_HUMAN
398	D G S F F L Y S R L T V D K S R W Q E G N V F S C S V M H E A L H N H Y T Q K S				GC4/118_HUMAN
441	L S L S P G K				GC1/118_HUMAN
437	L S L S P G K				GC2/118_HUMAN
438	L S L S L G K				GC4/118_HUMAN

FIG. 2B

5/9




FIG. 3




FIG. 4

7/9




FIG. 5

8/9




FIG. 6




FIG. 7

<110> GILLIES, Stephen D  
LO, Kin-Ming  
LAN, Yan  
WESOLOWSKI, John

<120> Enhancing the Circulating Half-life of  
Antibody-based Fusion Proteins

<130> LEX-003PC

<140>

<141>

<150> US 60/075,887

<151> 1998-02-25

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 447

<212> PRT

<213> Homo sapiens

<220>

<223> IGG-1 CHAIN C REGION

<400> 1

```

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1      5      10      15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20      25      30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35      40      45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50      55      60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65      70      75      80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85      90      95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100     105     110
Xaa Xaa Xaa Xaa Xaa Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115     120     125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130     135     140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145     150     155     160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165     170     175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180     185     190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195     200     205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210     215     220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225     230     235     240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245     250     255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu

```

260	265	270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys		
275	280	285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser		
290	295	300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys		
305	310	315
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile		
325	330	335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro		
340	345	350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu		
355	360	365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn		
370	375	380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser		
385	390	395
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg		
405	410	415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu		
420	425	430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys		
435	440	445

&lt;210&gt; 2

&lt;211&gt; 443

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;223&gt; IGG-2 CHAIN C REGION

&lt;400&gt; 2

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
1	5	10
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
20	25	30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
35	40	45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
50	55	60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
65	70	75
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
85	90	95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa		
100	105	110
Xaa Xaa Xaa Xaa Xaa Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu		
115	120	125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys		
130	135	140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser		
145	150	155
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser		
165	170	175



Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn  
 180 185 190  
 Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn  
 195 200 205  
 Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro  
 210 215 220  
 Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro  
 225 230 235 240  
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr  
 245 250 255  
 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn  
 260 265 270  
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg  
 275 280 285  
 Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val  
 290 295 300  
 Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser  
 305 310 315 320  
 Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys  
 325 330 335  
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu  
 340 345 350  
 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe  
 355 360 365  
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu  
 370 375 380  
 Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe  
 385 390 395 400  
 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly  
 405 410 415  
 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr  
 420 425 430  
 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 435 440

&lt;210&gt; 3

&lt;211&gt; 494

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;223&gt; IGG-3 CHAIN C REGION

&lt;400&gt; 3

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 65 70 75 80



<210> 4  
 <211> 444  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> IGG-4 CHAIN C REGION

<400> 4  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10 15  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 20 25 30  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 35 40 45  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 50 55 60  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 65 70 75 80  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 85 90 95  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 100 105 110  
 Xaa Xaa Xaa Xaa Xaa Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu  
 115 120 125  
 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys  
 130 135 140  
 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser  
 145 150 155 160  
 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser  
 165 170 175  
 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser  
 180 185 190  
 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn  
 195 200 205  
 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro  
 210 215 220  
 Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe  
 225 230 235 240  
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val  
 245 250 255  
 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe  
 260 265 270  
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro  
 275 280 285  
 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr  
 290 295 300  
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val  
 305 310 315 320  
 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala  
 325 330 335  
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln  
 340 345 350

Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly  
           355                                  360                                  365  
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro  
           370                                  375                                  380  
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser  
   385                                  390                                  395                                  400  
 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu  
                                   405                                  410                                  415  
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His  
                                   420                                  425                                  430  
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys  
           435                                  440

<210> 5  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 1

<400> 5  
 catcggtctt cccctg ~ 17

<210> 6  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 2

<400> 6  
 cggtcctgcg acgggaggtg ctgaggaaga gatgg 35

<210> 7  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 3

<400> 7  
 tcttcctcag cacctcccgt cgcaggaccg tcagtcttcc tcttc 45

<210> 8  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 4

<400> 8  
 gaggcgtggt cttgtag 17

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/03966

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K19/00 //C07K14/52, C07K14/55, C07K14/705, C07K14/73

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	REISFELD R A ET AL: "Recombinant antibody fusion proteins for cancer immunotherapy." CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1996) 213 ( PT 3) 27-53. REF: 67 JOURNAL CODE: DWQ. ISSN: 0070-217X., XP002107034 GERMANY: Germany, Federal Republic of see page 41 - page 48 ---	14-26
A	HARVILL E T ET AL: "In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation." JOURNAL OF IMMUNOLOGY, (1996 OCT 1) 157 (7) 3165-70. JOURNAL CODE: IFB. ISSN: 0022-1767., XP002107033 United States see page 3165 see page 3166, right-hand column --- -/-	14-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 June 1999

Date of making of the international search report

02.07.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentplan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 ope nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mennessier, T

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/03966

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHENG, XIN XIAO ET AL: "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation" J. IMMUNOL. (1995), 154(10), 5590-600 CODEN: JOIMA3; ISSN: 0022-1767, XP002082460 see page 5590 see page 5591, left-hand column; figure 1 see page 5593, left-hand column ---	14-26
A	GILLIES S D ET AL: "Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins." BIOCONJUGATE CHEMISTRY, (1993 MAY-JUN) 4 (3) 230-5. JOURNAL CODE: A1T. ISSN: 1043-1802., XP002107032 United States see page 230 see page 232, right-hand column - page 233, left-hand column ---	14-26
A	WO 97 33617 A (PROTEIN DESIGN LABS INC ;QUEEN CARY L (US); SCHNEIDER WILLIAM P (U) 18 September 1997 see page 19 - page 23; examples 2-6 see page 4, line 29 - page 5, line 2 see page 7, line 1-15 ---	14-26
A	WO 97 00319 A (SMITHKLINE BEECHAM PLC ;BROWNE MICHAEL JOSEPH (GB); CHAPMAN CONRAD) 3 January 1997 see page 10 - page 12; example 1 see claim 9 ---	14-26
T	GILLIES S D ET AL: "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors." CANCER RESEARCH, (1999 MAY 1) 59 (9) 2159-66. JOURNAL CODE: CNF. ISSN: 0008-5472., XP002107035 United States see the whole document -----	14-26

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US 99/03966

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-13  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remarks on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/03966

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-13

Claim 1 on which claims 1-12 are dependent is directed to an antibody based (Ab) fusion protein comprising an Ig-portion linked to a non-Ig protein portion and having a longer circulating half-life than the said non-Ig protein portion when unlinked.

It appears that this claimed subject-matter has no support in the description. No Ab fusion protein has been compared therein to its corresponding non-Ig protein portion as to their respective circulating half-lives (the only comparisons reported [see page 13, lines 1-3, and page 16, lines 8-9] concern modified Ab fusion proteins and their corresponding unmodified Ab fusion proteins).

Such a lack of support renders the subject-matter of claims 1-13 inconsistent with the content of the description.

The said inconsistent is such that carrying out a meaningful search with regard to the said claims has not been possible.

It is to be noted that even if the subject-matter of claims 1-13 would have been consistent with the content of the description, a meaningful search could not have been carried out as in the documents of the state of the art relating to Ab fusion proteins comprising an Ig-portion linked to a non-Ig protein portion (see the documents cited in the present report) the respective circulating half-lives of both the Ab fusion protein and the non-Ig protein portion thereof measured in the same experimental conditions are not indicated, a circumstance which renders any comparison impossible.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/03966

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9733617	A	18-09-1997	AU 2527397 A	01-10-1997
WO 9700319	A	03-01-1997	AU 6011096 A	15-01-1997
			CA 2224646 A	03-01-1997
			EP 0832219 A	01-04-1998